Nanobiotix S.A.(NBTX)Earnings, Financials & Key Ratios
NBTX•NASDAQ
$42.61
$2.06B mkt cap·Price updated May 7, 2026
AboutNanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.Show more
- Revenue-$12M-132.1%
- EBITDA-$67M-154.6%
- Net Income-$68M-71.6%
- EPS (Diluted)-1.44-33.3%
- Gross Margin100%
- EBITDA Margin575.17%+894.0%
- Operating Margin589.13%+896.6%
- Net Margin586.89%+635.3%
- Interest Coverage-8.46-152.1%
NBTX Key Insights
Nanobiotix S.A. (NBTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 175.7% free cash flow margin
- ✓Momentum leader: RS Rating 94 (top 6%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 28.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NBTX Price & Volume
Nanobiotix S.A. (NBTX) stock price & volume — 10-year historical chart
Loading chart...
NBTX Growth Metrics
Nanobiotix S.A. (NBTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM655.62%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM16.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM36.3%
Return on Capital
10 Years-99.28%
5 Years-110.88%
3 Years-149.83%
Last Year-260.51%
NBTX Recent Earnings
Nanobiotix S.A. (NBTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (60%)●Beat Revenue 3/12 qtrs (33%)
Q2 2026Latest
Mar 31, 2026EPS
$0.46
Est $0.30
-250.7%
Revenue
$4M
Est $52M
-93.2%
Q4 2025
Sep 30, 2025EPS
$0.13
Est $0.25
+45.9%
Revenue
$31M
Est $24M
+31.2%
Q2 2025
Apr 2, 2025EPS
$1.01
Est $0.62
-63.5%
Revenue
$22M
Est $4M
-709.2%
Q4 2024
Nov 12, 2024EPS
$0.50
Est $0.51
+2.5%
Revenue
$10M
Est $10M
-3.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 31, 2026 | $0.46vs $0.30-250.7% | $4Mvs $52M-93.2% |
| Q4 2025 | Sep 30, 2025 | $0.13vs $0.25+45.9% | $31Mvs $24M+31.2% |
| Q2 2025 | Apr 2, 2025 | $1.01vs $0.62-63.5% | $22Mvs $4M-709.2% |
| Q4 2024 | Nov 12, 2024 | $0.50vs $0.51+2.5% | $10Mvs $10M-3.5% |
Based on last 12 quarters of dataView full earnings history →
NBTX Peer Comparison
Nanobiotix S.A. (NBTX) competitors in Radiopharmaceuticals and Targeted Radiation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ARAY | 34.82M | 0.29 | -18.91 | 2.68% | -10.76% | -77.48% | 2.17 | |
 SENS | 223.9M | 5.36 | -3.23 | 56.89% | -208.13% | -131.45% | 0.68 | |
 ONCO | 1.38M | 0.40 | -0.09 | -67.7% | -17.21% | -189.85% | 0.00 | |
 CELC | 5.66B | 130.71 | -46.19 | -179% | 0.85 | |||
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 CLDX | 2.22B | 33.32 | -8.54 | -78.63% | -172.53% | -41.68% | 0.00 |
Compare NBTX vs Peers
Nanobiotix S.A. (NBTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NBTX Income Statement
Nanobiotix S.A. (NBTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.56M | 251.97K | 116K | 68K | 50K | 2.65M | 4.78M | 36.21M | -11.61M | 47.94M |
| Revenue Growth % | 486.76% | -83.83% | -53.96% | -41.38% | -26.47% | 5194% | 80.43% | 658.12% | -132.06% | 655.62% |
| Cost of Goods Sold | 436.31K | 345.59K | 0 | 0 | 0 | 0 | 985K | 0 | 0 | 0 |
| COGS % of Revenue | 28% | 137.16% | - | - | - | - | 20.62% | - | - | - |
| Gross Profit | 1.12M▲ 0% | -93.62K▼ 108.3% | 116K▲ 223.9% | 68K▼ 41.4% | 50K▼ 26.5% | 2.65M▲ 5194.0% | 3.79M▲ 43.2% | 36.21M▲ 855.1% | -11.61M▼ 132.1% | 47.94M▲ 0% |
| Gross Margin % | 72% | -37.16% | 100% | 100% | 100% | 100% | 79.38% | 100% | 100% | 100% |
| Gross Profit Growth % | 1292.54% | -108.35% | 223.9% | -41.38% | -26.47% | 5194% | 43.22% | 855.1% | -132.06% | - |
| Operating Expenses | 23.41M | 25.52M | 30.18M | 46.85M | 38.75M | 55.23M | 51.48M | 62.99M | 56.78M | 116.94M |
| OpEx % of Revenue | 1502.65% | 10127.88% | 26020.69% | 68892.65% | 77506% | 2086.36% | 1077.85% | 173.96% | -489.13% | - |
| Selling, General & Admin | 10.26M | 12.34M | 12.62M | 18.64M | 14.27M | 19.43M | 17.48M | 22.05M | 20.06M | 43.01M |
| SG&A % of Revenue | 658.33% | 4895.63% | 10878.45% | 27411.76% | 28542% | 734.19% | 366% | 60.9% | -172.79% | - |
| Research & Development | 16.92M | 16.34M | 20.89M | 30.41M | 24.33M | 30.38M | 32.64M | 38.4M | 40.54M | 75.66M |
| R&D % of Revenue | 1085.63% | 6483.7% | 18011.21% | 44722.06% | 48660% | 1147.64% | 683.33% | 106.04% | -349.22% | - |
| Other Operating Expenses | 160.23K | -337.89K | -3.33M | -2.2M | 152K | 5.41M | 1.36M | 2.54M | -3.82M | 128K |
| Operating Income | -21.85M▲ 0% | -25.27M▼ 15.6% | -30.07M▼ 19.0% | -46.78M▼ 55.6% | -36.43M▲ 22.1% | -52.58M▼ 44.3% | -46.7M▲ 11.2% | -26.78M▲ 42.7% | -68.39M▼ 155.4% | -68.99M▲ 0% |
| Operating Margin % | -1402.65% | -10027.88% | -25919.83% | -68792.65% | -72856% | -1986.36% | -977.85% | -73.96% | 589.13% | -143.9% |
| Operating Income Growth % | -27.49% | -15.61% | -19% | -55.58% | 22.13% | -44.34% | 11.18% | 42.66% | -155.39% | - |
| EBITDA | -21.42M | -24.92M | -29.5M | -45.01M | -34.67M | -51.02M | -45.2M | -26.23M | -66.77M | -66.82M |
| EBITDA Margin % | -1374.65% | -9890.72% | -25429.31% | -66189.71% | -69346% | -1927.43% | -946.44% | -72.44% | 575.17% | -139.38% |
| EBITDA Growth % | -28.36% | -16.36% | -18.36% | -52.58% | 22.96% | -47.14% | 11.4% | 41.98% | -154.58% | 31.11% |
| D&A (Non-Cash Add-back) | 436.31K | 345.59K | 569K | 1.77M | 1.75M | 1.56M | 1.5M | 551K | 1.62M | 2.17M |
| EBIT | -21.69M | -26.04M | -29.5M | -46.12M | -33.25M | -47.16M | -45.72M | -24.24M | -59.95M | -57.99M |
| Net Interest Income | 130.29K | -60K | -726K | -4.55M | -333K | -658K | -5.58M | -6.76M | -5.46M | -10.14M |
| Interest Income | 59.49K | 33.03K | 34K | 105K | 0 | 6.17M | 256K | 1.22M | 2.63M | 2.63M |
| Interest Expense | 102.2K | 108.37K | 847K | 4.79M | 333K | 671K | 5.84M | 7.98M | 8.09M | 15.13M |
| Other Income/Expense | 64.61K | -876K | -278K | -4.13M | 2.85M | 5.58M | -10.33M | -12.8M | 361K | -15.9M |
| Pretax Income | -21.79M▲ 0% | -26.14M▼ 20.0% | -30.34M▼ 16.1% | -50.91M▼ 67.8% | -33.61M▲ 34.0% | -47M▼ 39.8% | -57.03M▼ 21.4% | -39.58M▲ 30.6% | -68.03M▼ 71.9% | -84.89M▲ 0% |
| Pretax Margin % | -1398.5% | -10375.61% | -26159.48% | -74869.12% | -67228% | -1775.52% | -1194.16% | -109.31% | 586.02% | -177.06% |
| Income Tax | 90.42K | 20 | -449K | 3K | 9K | 5K | 10K | 120K | 101K | 224K |
| Effective Tax Rate % | -0.41% | -0% | 1.48% | -0.01% | -0.03% | -0.01% | -0.02% | -0.3% | -0.15% | -0.26% |
| Net Income | -21.88M▲ 0% | -26.14M▼ 19.5% | -29.9M▼ 14.4% | -50.91M▼ 70.3% | -33.62M▲ 34.0% | -47M▼ 39.8% | -57.04M▼ 21.4% | -39.7M▲ 30.4% | -68.13M▼ 71.6% | -85.12M▲ 0% |
| Net Margin % | -1404.31% | -10375.62% | -25772.41% | -74875% | -67246% | -1775.75% | -1194.37% | -109.64% | 586.89% | -177.53% |
| Net Income Growth % | -28.69% | -19.48% | -14.35% | -70.31% | 33.96% | -39.8% | -21.36% | 30.4% | -71.62% | 16.33% |
| Net Income (Continuing) | -21.88M | -26.14M | -30.34M | -50.91M | -33.59M | -47M | -57.04M | -39.7M | -68.13M | -85.12M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.43▲ 0% | -1.50▼ 4.9% | -1.52▼ 1.3% | -2.35▼ 54.6% | -1.38▲ 41.3% | -1.35▲ 2.2% | -1.64▼ 21.5% | -1.08▲ 34.1% | -1.44▼ 33.3% | -1.80▲ 0% |
| EPS Growth % | -19.17% | -4.9% | -1.33% | -54.61% | 41.28% | 2.17% | -21.48% | 34.15% | -33.33% | 36.3% |
| EPS (Basic) | -1.43 | -1.50 | -1.52 | -2.35 | -1.38 | -1.35 | -1.64 | -1.08 | -1.44 | - |
| Diluted Shares Outstanding | 15.28M | 17.48M | 19.63M | 21.63M | 24.39M | 34.73M | 34.85M | 36.93M | 47.27M | 47.42M |
| Basic Shares Outstanding | 15.28M | 17.43M | 19.62M | 21.63M | 24.39M | 34.73M | 34.85M | 36.76M | 47.27M | 47.42M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NBTX Balance Sheet
Nanobiotix S.A. (NBTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 26.89M | 53.11M | 42.65M | 46.13M | 125.25M | 93.06M | 52.36M | 87.34M | 61.47M | 39.89M |
| Cash & Short-Term Investments | 21.06M | 47.21M | 36.2M | 35.09M | 119.15M | 83.92M | 41.39M | 75.28M | 49.74M | 28.82M |
| Cash Only | 21.06M | 47.21M | 36.2M | 35.09M | 119.15M | 83.92M | 41.39M | 75.28M | 49.74M | 28.82M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 5.21K | 844K | 997K | 1.26M | 3.88M | 6.93M | 2.84M | 2.97M | 8.54M | 1.84M |
| Days Sales Outstanding | 1.22 | 1.22K | 3.14K | 6.74K | 28.32K | 955.04 | 217.2 | 29.91 | -268.35 | 43.75 |
| Inventory | -5.03M | -4.9M | 1.09M | 2.67M | 0 | -3.04M | 2.98M | 200K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | 1.1K | - | - | - |
| Other Current Assets | 5.02M | 4.73M | 5.33M | 4.43M | 0 | 3.04M | 2.17M | 6.33M | -1K | 7.31M |
| Total Non-Current Assets | 3.51M | 4.36M | 3.54M | 10.08M | 8.78M | 8.71M | 7.41M | 6.56M | 5.95M | 5.29M |
| Property, Plant & Equipment | 2.43M | 2.99M | 2.88M | 9.39M | 8.26M | 8.19M | 7.12M | 6.11M | 5.54M | 4.61M |
| Fixed Asset Turnover | 0.64x | 0.08x | 0.04x | 0.01x | 0.01x | 0.32x | 0.67x | 5.93x | -2.10x | 8.66x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 4.45K | 135.97K | 102K | 163K | 21K | 4K | 1K | 8K | 7K | 13K |
| Long-Term Investments | 242.22K | 272.93K | 176K | 131K | 105K | 98K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 382K | -1K | -1K | 421K | 291K | 443K | 406K | 1.83M |
| Total Assets | 30.4M▲ 0% | 57.47M▲ 89.0% | 46.2M▼ 19.6% | 56.2M▲ 21.7% | 134.03M▲ 138.5% | 101.77M▼ 24.1% | 59.77M▼ 41.3% | 93.9M▲ 57.1% | 67.42M▼ 28.2% | 45.17M▲ 0% |
| Asset Turnover | 0.05x | 0.00x | 0.00x | 0.00x | 0.00x | 0.03x | 0.08x | 0.39x | -0.17x | 0.65x |
| Asset Growth % | 15.08% | 89.02% | -19.61% | 21.67% | 138.47% | -24.07% | -41.27% | 57.1% | -28.2% | 95.53% |
| Total Current Liabilities | 8.25M | 9.35M | 11.6M | 14.35M | 19.04M | 36.84M | 37.94M | 49.87M | 58.94M | 63.04M |
| Accounts Payable | 4.37M | 5.14M | 4.54M | 6.15M | 5.57M | 5M | 4M | 6.7M | 4.48M | 4.23M |
| Days Payables Outstanding | 3.66K | 5.43K | - | - | - | - | 1.48K | - | - | - |
| Short-Term Debt | 1.08M | 770K | 500K | 500K | 3.67M | 7.08M | 3.6M | 3.82M | 3.66M | 3.49M |
| Deferred Revenue (Current) | 2.23M | 2.96M | 93K | 7.11M | 0 | 16.77M | 16.57M | 0 | 18.16M | 36.39M |
| Other Current Liabilities | 556.3K | 807.47K | 567K | -6.7M | 7.06M | 5.39M | 7.41M | 19.86M | 8.27M | 40.79M |
| Current Ratio | 3.26x | 5.68x | 3.68x | 3.22x | 6.58x | 2.53x | 1.38x | 1.75x | 1.04x | 1.04x |
| Quick Ratio | 3.87x | 6.20x | 3.58x | 3.03x | 6.58x | 2.61x | 1.30x | 1.75x | 1.04x | 1.04x |
| Cash Conversion Cycle | - | - | - | - | - | - | -160.03 | - | - | 43.75 |
| Total Non-Current Liabilities | 4.76M | 4.19M | 20.36M | 43.77M | 44.52M | 38.13M | 48.88M | 45.87M | 74.19M | 51.09M |
| Long-Term Debt | 4.58M | 3.75M | 20.02M | 37.62M | 39.12M | 32.42M | 44.04M | 41.66M | 43.01M | 44.12M |
| Capital Lease Obligations | 0 | 0 | 0 | 5.81M | 4.99M | 5.39M | 4.57M | 3.88M | 2.97M | 12.68M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 175.21K | 446.27K | 334K | 332K | 414K | 318K | 270K | 325K | 28.21M | 40.89M |
| Total Liabilities | 13M | 13.54M | 31.95M | 58.11M | 63.56M | 74.98M | 86.81M | 95.74M | 133.12M | 114.13M |
| Total Debt | 5.67M | 4.73M | 20.52M | 44.53M | 48.98M | 46.02M | 53.17M | 50.56M | 50.9M | 51.24M |
| Net Debt | -15.39M | -42.48M | -15.68M | 9.43M | -70.17M | -37.9M | 11.78M | -24.72M | 1.17M | 22.42M |
| Debt / Equity | 0.33x | 0.11x | 1.44x | - | 0.70x | 1.72x | - | - | - | -0.74x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.77x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.34x |
| Interest Coverage | -213.84x | -233.16x | -35.50x | -9.76x | -109.39x | -78.36x | -8.00x | -3.35x | -8.46x | -3.83x |
| Total Equity | 17.4M▲ 0% | 43.92M▲ 152.4% | 14.24M▼ 67.6% | -1.91M▼ 113.4% | 70.47M▲ 3791.4% | 26.79M▼ 62.0% | -27.05M▼ 201.0% | -1.84M▲ 93.2% | -65.7M▼ 3463.1% | -68.95M▲ 0% |
| Equity Growth % | 11.45% | 152.45% | -67.57% | -113.4% | 3791.36% | -61.98% | -200.95% | 93.18% | -3463.07% | -3527% |
| Book Value per Share | 1.14 | 2.51 | 0.73 | -0.09 | 2.89 | 0.77 | -0.78 | -0.05 | -1.39 | -1.45 |
| Total Shareholders' Equity | 17.4M | 43.92M | 14.24M | -1.91M | 70.47M | 26.79M | -27.05M | -1.84M | -65.7M | -68.95M |
| Common Stock | 478.96K | 589K | 589K | 672K | 1.03M | 1.04M | 1.05M | 1.41M | 1.42M | 1.45M |
| Retained Earnings | -21.88M | -26.14M | -30.34M | -50.91M | -33.59M | -47M | -57.04M | -39.7M | -68.13M | -5.38M |
| Treasury Stock | -57.77K | -27K | -124K | -169K | -196K | -202K | -228K | -228K | -228K | -228K |
| Accumulated OCI | -35.44M | -54.28M | -78.68M | -104.64M | -152.51M | -182.82M | -226.58M | -276.07M | -311.51M | -377.53M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NBTX Cash Flow Statement
Nanobiotix S.A. (NBTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.28M | -21.03M | -25.98M | -41.17M | -27.54M | -29.87M | -37.1M | -12.48M | -19.55M | -19.55M |
| Operating CF Margin % | -1173.46% | -8347.41% | -22400.86% | -60542.65% | -55076% | -1128.52% | -776.88% | -34.46% | 168.41% | - |
| Operating CF Growth % | -8.7% | -15.04% | -23.55% | -58.43% | 33.11% | -8.48% | -24.21% | 66.38% | -56.71% | -393.51% |
| Net Income | -21.88M | -26.14M | -30.34M | -50.91M | -33.59M | -47M | -57.04M | -39.7M | -68.13M | -85.12M |
| Depreciation & Amortization | 482.79K | 403.85K | 619K | 1.77M | 1.75M | 1.56M | 1.5M | 1.51M | 1.62M | 3.19M |
| Stock-Based Compensation | 1.99M | 2.61M | 1.87M | 4.32M | 2.92M | 3.2M | 3.17M | 3.3M | 4.3M | 8.41M |
| Deferred Taxes | 0 | 0 | 0 | 2.1M | 5.64M | 152K | 0 | 120K | 101K | 101K |
| Other Non-Cash Items | -75.17K | 430.32K | 796K | 3.08M | -4.34M | 678K | 12.96M | 12.37M | 28.28M | 25.31M |
| Working Capital Changes | 1.2M | 1.67M | 1.08M | -1.52M | 73K | 11.54M | 2.3M | 9.92M | 14.28M | 15.94M |
| Change in Receivables | 74.82K | -164.29K | 144K | -85K | -51K | 62K | -101K | -806K | 355K | 1.68M |
| Change in Inventory | 0 | 0 | 0 | -2.06M | 995K | 281K | -2.91M | 0 | 0 | 0 |
| Change in Payables | 788.69K | 785.95K | 633K | 2.06M | -995K | -281K | 2.91M | 8.68M | 0 | 0 |
| Cash from Investing | -444.99K | -1.46M | 71K | -1.46M | -112K | -242K | 138K | -349K | -955K | -1.14M |
| Capital Expenditures | -400.1K | -1.46M | -506K | -1.44M | -107K | -233K | -93K | -328K | -846K | -1M |
| CapEx % of Revenue | 25.68% | 581.16% | 436.21% | 2123.53% | 214% | 8.8% | 1.95% | 0.91% | -7.29% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -44.88K | -224K | 577K | 1K | -1K | 0 | 0 | -21K | -109K | -120K |
| Cash from Financing | 22.9M | 48.53M | 14.85M | 41.49M | 111.77M | -5.18M | -5.65M | 46.77M | -5.13M | 40.94M |
| Debt Issued (Net) | 1.22M | -1.03M | 15.07M | 12.43M | 9.17M | -3.74M | -4.74M | -3.62M | -4.16M | -8.69M |
| Equity Issued (Net) | 1000K | 1000K | 0 | 1000K | 1000K | 0 | 0 | 1000K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -1.43M | -3.56M | -223K | -461K | -11.05M | -1.44M | -916K | -9.77M | -980K | 49.64M |
| Net Change in Cash | 4.05M▲ 0% | 26.15M▲ 545.0% | -11.01M▼ 142.1% | -1.11M▲ 89.9% | 84.06M▲ 7679.5% | -35.23M▼ 141.9% | -42.53M▼ 20.7% | 33.9M▲ 179.7% | -25.55M▼ 175.4% | 132.21M▲ 0% |
| Free Cash Flow | -18.68M▲ 0% | -22.5M▼ 20.4% | -26.49M▼ 17.8% | -42.61M▼ 60.9% | -27.64M▲ 35.1% | -30.11M▼ 8.9% | -37.2M▼ 23.6% | -12.81M▲ 65.6% | -20.4M▼ 59.2% | -33.17M▲ 0% |
| FCF Margin % | -1199.14% | -8928.57% | -22837.07% | -62666.18% | -55290% | -1137.33% | -778.83% | -35.39% | 175.72% | -69.18% |
| FCF Growth % | -2.01% | -20.41% | -17.75% | -60.86% | 35.13% | -8.9% | -23.56% | 65.55% | -59.21% | 53.79% |
| FCF per Share | -1.22 | -1.29 | -1.35 | -1.97 | -1.13 | -0.87 | -1.07 | -0.35 | -0.43 | -0.43 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.80x | 0.87x | 0.81x | 0.82x | 0.64x | 0.65x | 0.31x | 0.29x | 0.39x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 336K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NBTX Key Ratios
Nanobiotix S.A. (NBTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -132.57% | -85.27% | -102.8% | -825.6% | -98.08% | -96.66% | - | - | - | 215.11% |
| Return on Invested Capital (ROIC) | -628.39% | -1099.69% | - | -1153.33% | -698.84% | - | - | - | - | 117.22% |
| Gross Margin | 72% | -37.16% | 100% | 100% | 100% | 100% | 79.38% | 100% | 100% | 100% |
| Net Margin | -1404.31% | -10375.62% | -25772.41% | -74875% | -67246% | -1775.75% | -1194.37% | -109.64% | 586.89% | -177.53% |
| Debt / Equity | 0.33x | 0.11x | 1.44x | - | 0.70x | 1.72x | - | - | - | -0.74x |
| Interest Coverage | -213.84x | -233.16x | -35.50x | -9.76x | -109.39x | -78.36x | -8.00x | -3.35x | -8.46x | -3.83x |
| FCF Conversion | 0.84x | 0.80x | 0.87x | 0.81x | 0.82x | 0.64x | 0.65x | 0.31x | 0.29x | 0.39x |
| Revenue Growth | 486.76% | -83.83% | -53.96% | -41.38% | -26.47% | 5194% | 80.43% | 658.12% | -132.06% | 655.62% |
NBTX Frequently Asked Questions
Nanobiotix S.A. (NBTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nanobiotix S.A. (NBTX) reported $47.9M in revenue for fiscal year 2024. This represents a 3424% increase from $1.4M in 2011.
Nanobiotix S.A. (NBTX) saw revenue decline by 132.1% over the past year.
Nanobiotix S.A. (NBTX) reported a net loss of $85.1M for fiscal year 2024.
Dividend & Returns
Nanobiotix S.A. (NBTX) had negative free cash flow of $33.2M in fiscal year 2024, likely due to heavy capital investments.
Explore More NBTX
Nanobiotix S.A. (NBTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates